| 21.08 13:57 | dpa-AFX: Bristol Myers : FDA Accepts SBLA For First-Line Treatment Of Unresectable Hepatocellular Carcinoma |
| 21.08 13:43 | dpa-AFX: *BRISTOL MYERS SQUIBB: FDA ACCEPTS SBLA FOR OPDIVO + YERVOY FOR 1ST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA |
| 19.08 16:03 | dpa-AFX: EMA Validates Bristol Myers Squibb's Application For CAR T Cell Therapy Breyanzi |
| 19.08 15:03 | dpa-AFX: *EMA VALIDATES BRISTOL MYERS SQUIBB'S APPLICATION FOR CAR T CELL THERAPY BREYANZI FOR R/R FOLLICULAR LYMPHOMA |
| 16.08 12:28 | MARKT USA/Wall Street nach Rally behauptet erwartet |
| 13.08 08:27 | dpa-AFX: Evotec erhält 75 Millionen Dollar Meilensteinzahlung von Bristol Myers Squibb |
| 13.08 08:27 | Evotec erhält 75 Millionen Dollar Meilensteinzahlung von Bristol Myers Squibb |
| 13.08 08:22 | dpa-AFX: Evotec erhält 75 Millionen Dollar Meilensteinzahlung von Bristol Myers Squibb |
| 13.08 07:59 | Bristol Myers zahlt Evotec 75 Mio Dollar für Fortschritte bei Molecular Glues |
| 13.08 07:52 | dpa-AFX: Evotec Secures $75 Mln In Milestone Payments From Bristol Myers Amid Pipeline Advancements |
| 13.08 07:37 | dpa-AFX: *EVOTEC ANNOUNCES STRONG PROGRESS IN STRATEGIC PROTEIN DEGRADATION PARTNERSHIP WITH BRISTOL MYERS SQUIBB |
| 13.08 07:33 | dpa-AFX: *EVOTEC: LEISTUNGS- UND PROGRAMMABHÄNGIGE ZAHLUNGEN IN HÖHE VON 75 MIO USD |
| 13.08 07:32 | dpa-AFX: *EVOTEC: FORTSCHRITTE IN PROTEIN DEGRADATION-PARTNERSCHAFT MIT BRISTOL MYERS |
| 11.08 17:21 | dpa-AFX: Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray |
| 08.08 10:40 | Evotec erhält 25 Mio USD von Bristol Myers Squibb in Partnerschaft |
| 08.08 08:21 | dpa-AFX: Evotec Announces Progress In Strategic Neuroscience Collaboration With Bristol Myers Squibb |
| 08.08 07:38 | dpa-AFX: *EVOTEC ANNOUNCES PROGRESS IN STRATEGIC NEUROSCIENCE PARTNERSHIP WITH BRISTOL MYERS SQUIBB |
| 08.08 07:31 | dpa-AFX: *EVOTEC: PIPELINE-ZAHLUNG 25 MIO USD |
| 08.08 07:31 | dpa-AFX: *EVOTEC: FORTSCHRITT IN STRATEGISCHER NEUROLOGIE-PARTNERSCHAFT MIT BMS |
| 29.07 17:02 | dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR BRISTOL-MYERS SQUIBB AUF 56 (50) USD - 'KAUFEN' |
|
|
